Quarterly ResultMay 14, 2026, 05:07 PM
Bone Biologics Q1 Net Loss Narrows to $0.77M; Cash $4.53M
AI Summary
Bone Biologics Corp reported a net loss of $0.77 million for the first quarter of 2026, a significant improvement from the $1.02 million net loss in the prior year. The company's cash balance stood at $4.53 million as of March 31, 2026, which is expected to fund operations into the fourth quarter of 2026. The company continues to face substantial doubt about its ability to continue as a going concern and plans to seek additional financing. Research and development expenses decreased by 66.6% year-over-year.
Key Highlights
- Net loss for Q1 2026 narrowed to $765,988, down 24.7% from $1,017,092 in Q1 2025.
- Loss per share improved to $(0.43) in Q1 2026 from $(1.92) in Q1 2025.
- Cash balance was $4,530,040 as of March 31, 2026, down from $5,334,322 at December 31, 2025.
- Research and development expenses decreased 66.6% to $141,597 in Q1 2026 from $423,576 in Q1 2025.
- Net cash used in operating activities was $804,282 in Q1 2026, an improvement from $926,125 in Q1 2025.
- Accumulated deficit reached $88.9 million as of March 31, 2026.
- Operating expenditures for the next twelve months are estimated at $5.4 million.
- The company had 2,753,827 warrants outstanding as of March 31, 2026.